Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

ABSTRACT:

Background

Incorporation of multiple enrichment biomarkers into prospective clinical trials is an active area of investigation, but the factors that determine clinical trial enrollment following a molecular prescreening program have not been assessed.

Patients and methods

Patients with 5-fluorouracil-refractory metastatic colorectal cancer at the MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion phase I or II clinical trials with a therapy targeted to an aberration detected in the patient, based on testing by immunohistochemistry, targeted gene sequencing panels, and CpG island methylation phenotype assays.

Results

Between August 2010 and December 20

SUBMITTER: Overman MJ 

PROVIDER: S-EPMC6276928 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature